In a report released yesterday, Naz Rahman from Maxim Group maintained a Hold rating on First Wave Bio (FWBI – Research Report). The company’s shares closed last Friday at $1.41, close to its 52-week low of $1.27.
According to TipRanks.com, Rahman has 0 stars on 0-5 stars ranking scale with an average return of -35.0% and a 4.3% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Galmed Pharmaceuticals, and Vertex Pharmaceuticals.
First Wave Bio has an analyst consensus of Hold.
The company has a one-year high of $26.30 and a one-year low of $1.27. Currently, First Wave Bio has an average volume of 1.61M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. It focuses on MS1819-SD, and B-Lactamase program products. The company was founded on January 30, 2014 and is headquartered in Brooklyn, NY.
Read More on FWBI: